Oxy-17® is a non-radioactive, in vivo biomarker for oxygen metabolism in tissue using MRI. Oxy-17® delivers naturally occurring Oxygen-17 gas (¹⁷O₂) to tissue in concentrations above natural abundance, by inhalation or injection, for real-time, in vivo quantitation of oxygen metabolism in brain, heart and other organs for animal research, drug discovery, drug screening, pre-clinical and human clinical use. One consistent biomarker throughout.

Introducing: A new oxygen transporter to tissue

**OxyToT™ for Oxy-17®**

Oxy-17® is used with OxyToT™ to deliver OxyGas™ (O-17 gas) via intravenous delivery for scientific and medical uses as a bioscale contrast medium for real-time, in vivo quantitation of oxygen metabolism with MR imaging.
Annual Review of Pharmacology and Toxicology

Volume 51 • February 2011 • Online & In Print • http://pharmtox.annualreviews.org

Editor: Arthur K. Cho, University of California, Los Angeles

The Annual Review of Pharmacology and Toxicology, in publication since 1961, covers the significant developments in the fields of pharmacology and toxicology, including receptors, transporters, enzymes, and chemical agents; drug development science; systems such as the immune system, central and autonomic nervous systems, gastrointestinal system, cardiovascular system, endocrine system, and pulmonary system; and special topics.

Access this and all Annual Reviews journals via your institution at www.annualreviews.org

Personal copies available at a reduced rate. Institutional site license options available. Contact Annual Reviews for details.

PLANNED TABLE OF CONTENTS:

• A 40-Year Journey in Search of Selective Antiviral Chemotherapy, Erik De Clercq

• microRNAs: Master Regulators as Potential Therapeutics in Cancer, Michela Garofalo, Carlo M. Croce

• Physiologically-Based Pharmacokinetics in Drug Development and Regulatory Science, Malcolm Rowland, Carl Peck, Geoffrey Tucker

• Transcriptional and Epigenetic Regulation of Opioid Receptor Genes: Present and Future, Li-Na Wei, Horace H. Loh

• Membrane Receptor for Thyroid Hormone: Physiologic and Pharmacologic Implications, Paul J. Davis, Faith B. Davis, Shaker A. Mousa, Mary K. Luidens, Hung-Yun Lin

• Strategies to Discover Unexpected Targets for Drugs Active at G Protein–Coupled Receptors, John A. Allen, Bryan L. Roth

• Bioactivation of Drugs: Risk and Drug Design, John S. Walsh, Gerald T. Miwa

• Mechanisms of the Anti-Cancer and Anti-Inflammatory Actions of Vitamin D, Aruna V. Krishnan, David Feldman

• Spatiotemporal Regulation of Small GTPases as Revealed by Probes Based on the Principle of Förster Resonance Energy Transfer (FRET): Implications for Signaling and Pharmacology, Etsuko Kiyokawa, Kazuhiro Aoki, Takeshi Nakamura, Michiyuki Matsuda

• Mechanisms of Monoclonal Antibody–Drug Interactions, Honghui Zhou, Mary Ann Mascelli

• Molecular Mechanisms and Treatment Options for Muscle Wasting Diseases, Markus A. Ruegg, David J. Glass

• Curing HIV: Pharmacologic Approaches to Target HIV-1 Latency, Shailesh K. Choudhary, David M. Margolis

• Modulation of Monoamine Receptors by Adaptor Proteins and Lipid Rafts: Role in Some Effects of Centrally Acting Drugs and Therapeutic Agents, Karl Bjork, Per Svenningsson

• Orexin Receptors: Pharmacology and Therapeutic Opportunities, Thomas E. Scammell, Christopher J. Winrow

• Macrophages and Tissue Injury: Agents of Defense or Destruction? Debra L. Laskin, Vasanthi R. Sunil, Carol R. Gardner, Jeffrey D. Laskin

• Drugging the Cancer Stem Cell Compartment: Lessons Learned from the Hedgehog and Wnt Signal Transduction Pathways, Michael E. Dodge, Lawrence Lum